1887
  1. الرئيسية
  2. A-Z Publications
  3. Global Cardiology Science and Practice
  4. المجلد 2015, العدد 2
  5. المقالة
Volume 2015, Issue 2
  • ISSN: 2305-7823
  • E-ISSN:

ملخص

Angina that is refractory to conventional medical therapy and revascularisation, remains challenging to manage and poses significant burden to patients. Elevated lipoprotein(a) [Lp(a)] has emerged as an important independent cardiovascular risk factor and predictor of adverse outcomes in atherosclerotic disease. The prevalence of raised Lp(a) amongst patients with refractory angina has not yet been defined. To establish the prevalence of raised [Lp(a)] >500 mg/L in patients with refractory angina. We conducted an epidemiological screening pilot study in 75 patients with refractory angina from a UK tertiary cardiac centre. We determined the proportion of the cohort with raised Lp(a) >500 mg/L using an isoform-insensitive method. In addition, a full fasting lipid profile (including: LDL cholesterol, HDL cholesterol, total cholesterol to HDL ratio and triglycerides) was obtained. Patients were also asked about the presence of conventional cardiovascular risk factors. Our study demonstrated that 60% of the 75 patients with refractory angina had raised Lp(a) levels of >500 mg/L. The median and inter-quartile range of Lp(a) values were 771 mg/L (162 mg/L,1260 mg/L) respectively. This high prevalence of raised Lp(a) detected in our cohort with refractory angina may suggest a causal role. Further research is necessary to confirm this association and prospective studies are needed to explore the potential therapeutic benefit of Lp(a) reduction in patients with refractory angina.

© 2015 Khan, Rhodes, Pottle, Banya, Smith, Kabir, Ilsely, Pennell, Barbir, licensee Bloomsbury Qatar Foundation Journals.
Loading

جارٍ تحميل قياسات المقالة...

/content/journals/10.5339/gcsp.2015.28
٢٠١٥-٠٧-٠٧
٢٠٢٤-٠٨-٣١
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2015/2/gcsp.2015.28.html?itemId=/content/journals/10.5339/gcsp.2015.28&mimeType=html&fmt=ahah

References

  1. Kim MC, Kini A, Sharma SK. Refractory angina pectoris. Mechanism and therapeutic options. J Am Coll Cardiol. 2002; 39:6:923–934.
     [Google الباحث العلمي]
  2. Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, Follath F, Hellemans I, Herlitz J, Lüscher T, Pasic M, Thelle D. The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina. Eur Heart J. 2002; 23:5:355–370.
     [Google الباحث العلمي]
  3. DeJongste MJL, Tio RA, Foreman RD. Chronic therapeutically refractory angina pectoris. Heart. 2004; 90::225–230.
     [Google الباحث العلمي]
  4. Soran O. Treatment options for refractory angina pectoris: Enhanced external counterpulsation therapy. Curr Treat Options Cardiovasc Med. 2009; 11::54–60.
     [Google الباحث العلمي]
  5. Manchanda A, Aggarwal A, Aggarwal N, Soran O. Management of refractory angina pectoris. Cardiology Journal. 2011; 18:4:343–351.
     [Google الباحث العلمي]
  6. Berg K. A new serum type system in man: the Lp system. ActaPatholMicrobiolScand. 1963; 59::369–382.
     [Google الباحث العلمي]
  7. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994; 24::444–453.
     [Google الباحث العلمي]
  8. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000; 102:10:1082–1085.
     [Google الباحث العلمي]
  9. Solanki US, Kumar A. Lipoprotein(a) in essential hypertension patients. Indian Medical Gazette. 2013; Vol.CXLVII:No.8:292–295.
     [Google الباحث العلمي]
  10. Erqou S, Kaptoge S, Perry PL, Angelantonio ED, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and non-vascular mortality. JAMA. 2009; 302::412–423.
     [Google الباحث العلمي]
  11. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31::2844–2853.
     [Google الباحث العلمي]
  12. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009; 361:26:2518–2528.
     [Google الباحث العلمي]
  13. Bambauer R, Olbricht CJ, Schoeppe E. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results. Ther Apher Dial. 1997; 1::242–248.
     [Google الباحث العلمي]
  14. Stephen Bohl S, Kassner U, Eckardt R, Utz W, Mueller-Nordhorn J, Busjahn A, Thomas HP, Abdel-Aty H, Klingel R, Marcovina S, Dietz R, Steinhagen-Thiessen E, Schulz-Menger J, Vogt A. Single Lipoprotein Apheresis Session Improves Cardiac Microvascular Function in Patients with Elevated Lipoprotein(a): Detection by Stress/Rest Perfusion Magnetic Resonance Imaging. TherApher Dial. 2009; 13::129–137.
     [Google الباحث العلمي]
  15. HPS2-THRIVE Collaborative Group. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine. 2014; 371:3:203–212. doi:10.1056/NEJMoa1300955 .
     [Google الباحث العلمي]
  16. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials. J Am Coll Cardiol. 2014; 63:13:1278–1288.
     [Google الباحث العلمي]
  17. Merki E, Graham M, Taleb A, Leibundgut G, Yang X, Miller ER, Fu W, Mullick AE, Lee R, Willeit P, Crooke RM, Witztum JL, Tsimikas S. Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein(a) and Lipoprotein (a) in Transgenic Mice. J Am Coll Cardiol. 2011; 57::1611–1621.
     [Google الباحث العلمي]
  18. Borberg H. Comparison of different Lp(a) elimination techniques: A retrospective evaluation. Trans Apheres Sci. 2009; 41:1:61–65.
     [Google الباحث العلمي]
/content/journals/10.5339/gcsp.2015.28
Loading
High prevalence of raised lipoprotein(a) in patients with refractory angina
Global Cardiology Science and Practice 2015, 28 (٢٠١٥); https://doi.org/10.5339/gcsp.2015.28
/content/journals/10.5339/gcsp.2015.28
/content/journals/10.5339/gcsp.2015.28
Loading

جارٍ تحميل البيانات والوسائط...

  • نوع المستند: Research Article
الموضوعات الرئيسية Coronary artery disease, Lipoprotein (a), Refractory angina and Risk factors
هذه الخانة مطلوبة
يُرجى إدخال عنوان بريد إلكتروني صالح
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error